Increased Risk of Dementia in Patients with Atopic Dermatitis: A Nationwide Population-Based Cohort Study
DOI:
https://doi.org/10.2340/actadv.v103.4557Keywords:
atopic dermatitis, Alzheimer’s disease, dementia, diabetes mellitus, vascular dementiaAbstract
Atopic dermatitis (AD) is a chronic inflammatory skin disorder with bimodal incidence peaks in early childhood and middle-aged and older adults. Few studies have focused on the risk of dementia in AD. The aims of this study were to analyse the incidence, and risk factors for dementia in patients with AD. This nationwide population-based retrospective cohort study enrolled 38,391 adults ≥ 40 years of age with AD and 2,643,602 controls without AD from the Korean National Health Insurance System (NHIS) database from 2009 to 2016. The cumulative incidence probability of all-cause dementia, Alzheimer’s disease, or vascular dementia at 8 years was 50, 39, and 7 per 1,000 person-years in patients with AD, respectively. The adjusted risks of all-cause dementia (hazard ratio (HR), 1.072; 95% confidence interval (95% CI) 1.026–1.120), and Alzheimer’s disease (HR 1.051; 95% CI 1.000–1.104) were increased in patients with AD. The effect of AD on the development of all-cause dementia and Alzheimer’s dementia varied according to age and diabetes mellitus (all p for interaction, < 0.05). The risks of all-cause dementia and Alzheimer’s disease were increased in patients with AD. Management of modifiable risk factors is important for preventing dementia in patients with AD.
Downloads
References
Prince MJ, Guerchet MM, Prina M. The epidemiology and impact of dementia: current state and future trends. WHO Thematic Briefing. Geneva: World Health Organization, 2015.
Choi YJ, Kim S, Hwang YJ, Kim C. Prevalence of dementia in Korea based on hospital utilization data from 2008 to 2016. Yonsei Med J 2021; 62: 948.
https://doi.org/10.3349/ymj.2021.62.10.948 DOI: https://doi.org/10.3349/ymj.2021.62.10.948
Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu Y-T, Prina M. World Alzheimer Report 2015 - the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer's Disease International, 2015.
Pasqualetti G, Brooks DJ, Edison P. The role of neuroinflammation in dementias. Curr Neurol Neurosci Rep 2015; 15: 17.
https://doi.org/10.1007/s11910-015-0531-7 DOI: https://doi.org/10.1007/s11910-015-0531-7
Laughter M, Maymone M, Mashayekhi S, Arents B, Karimkhani C, Langan S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol 2021; 184: 304-309.
https://doi.org/10.1111/bjd.19580 DOI: https://doi.org/10.1111/bjd.19580
Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233-246.
https://doi.org/10.1111/j.1600-065X.2011.01027.x DOI: https://doi.org/10.1111/j.1600-065X.2011.01027.x
Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 2019; 143: 1-11.
https://doi.org/10.1016/j.jaci.2018.10.032 DOI: https://doi.org/10.1016/j.jaci.2018.10.032
Silverberg JI. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol 2017; 35: 360-366.
https://doi.org/10.1016/j.clindermatol.2017.03.008 DOI: https://doi.org/10.1016/j.clindermatol.2017.03.008
Bekić S, Martinek V, Talapko J, Majnarić L, Vasilj Mihaljević M, Škrlec I. Atopic dermatitis and comorbidity. Healthcare 2020; 8: 70.
https://doi.org/10.3390/healthcare8020070 DOI: https://doi.org/10.3390/healthcare8020070
Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131: 428-433.
https://doi.org/10.1016/j.jaci.2012.10.041 DOI: https://doi.org/10.1016/j.jaci.2012.10.041
Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, et al. Association of atopic dermatitis severity with cognitive function in adults. J Am Acad Dermatokl 2020; 83: 1349-1359.
https://doi.org/10.1016/j.jaad.2020.05.041 DOI: https://doi.org/10.1016/j.jaad.2020.05.041
Pan T-L, Bai Y-M, Cheng C-M, Tsai S-J, Tsai C-F, Su T-P, et al. Atopic dermatitis and dementia risk: a nationwide longitudinal study. Ann Allergy Asthma Immunol 2021; 127: 200-205.
https://doi.org/10.1016/j.anai.2021.03.001 DOI: https://doi.org/10.1016/j.anai.2021.03.001
Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol 2016; 3: 263-292.
https://doi.org/10.1007/s12016-015-8488-5 DOI: https://doi.org/10.1007/s12016-015-8488-5
Lee K, Jo YY, Chung G, Jung JH, Kim YH, Park C-K. Functional importance of transient receptor potential (TRP) channels in neurological disorders. Front Cell Dev Biol 2021; 9: 410.
https://doi.org/10.3389/fcell.2021.611773 DOI: https://doi.org/10.3389/fcell.2021.611773
Afkhami-Goli A, Noorbakhsh F, Keller AJ, Vergnolle N, Westaway D, Jhamandas JH, et al. Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease. J Immunol 2007; 179: 5493-5503.
https://doi.org/10.4049/jimmunol.179.8.5493 DOI: https://doi.org/10.4049/jimmunol.179.8.5493
Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N. Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol 2014; 70: 882-888.
https://doi.org/10.1016/j.jaad.2014.01.867 DOI: https://doi.org/10.1016/j.jaad.2014.01.867
Lyubchenko T, Collins HK, Goleva E, Leung DY. Skin tape sampling technique identifies proinflammatory cytokines in atopic dermatitis skin. Ann Allergy Asthma Immunol 2021; 126: 46-53.e42.
https://doi.org/10.1016/j.anai.2020.08.397 DOI: https://doi.org/10.1016/j.anai.2020.08.397
Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A. Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis 2014; 40: 297-308.
https://doi.org/10.3233/JAD-132081 DOI: https://doi.org/10.3233/JAD-132081
Demirci S, Aynalı A, Demirci K, Demirci S, Arıdoğan BC. The serum levels of resistin and its relationship with other proinflammatory cytokines in patients with Alzheimer's disease. Clin Psychopharmacol Neurosci 2017; 15: 59.
https://doi.org/10.9758/cpn.2017.15.1.59 DOI: https://doi.org/10.9758/cpn.2017.15.1.59
Taha RA, Minshall EM, Leung DY, Boguniewicz M, Luster A, Muro S, et al. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J Allergy Clin Immunol 2000; 105: 1002-1007.
https://doi.org/10.1067/mai.2000.106483 DOI: https://doi.org/10.1067/mai.2000.106483
Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia 2015; 63: 2274-2284.
https://doi.org/10.1002/glia.22892 DOI: https://doi.org/10.1002/glia.22892
Choi C, Jeong J-H, Jang JS, Choi K, Lee J, Kwon J, et al. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J Clin Neurol 2008; 4: 84-88.
https://doi.org/10.3988/jcn.2008.4.2.84 DOI: https://doi.org/10.3988/jcn.2008.4.2.84
Schut C, Mochizuki H, Grossman SK, Lin AC, Conklin CJ, Mohamed FB, et al. Brain processing of contagious itch in patients with atopic dermatitis. Front Psychol 2017; 8: 1267.
https://doi.org/10.3389/fpsyg.2017.01267 DOI: https://doi.org/10.3389/fpsyg.2017.01267
Zhang Z-G, Li Y, Ng CT, Song Y-Q. Inflammation in Alzheimer's disease and molecular genetics: recent update. Arch Immunol Ther Exp 2015; 63: 333-344.
https://doi.org/10.1007/s00005-015-0351-0 DOI: https://doi.org/10.1007/s00005-015-0351-0
Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, García-Eulate M, Arbizu J, et al. Early-and late-onset Alzheimer's disease: are they the same entity? Neurologia 2018; 33: 244-253.
https://doi.org/10.1016/j.nrleng.2015.08.009 DOI: https://doi.org/10.1016/j.nrleng.2015.08.009
Kim MJ, Kang TW, Cho EA, Kim HS, Min JA, Park H, et al. Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul Metropolitan Area, Korea. J Korean Med Sci 2010; 25: 1828-1830.
https://doi.org/10.3346/jkms.2010.25.12.1828 DOI: https://doi.org/10.3346/jkms.2010.25.12.1828
Pavel AB, Zhou L, Diaz A, Ungar B, Dan J, He H, et al. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. J Am Acad Dermatol 2020; 82: 690-699.
https://doi.org/10.1016/j.jaad.2019.10.039 DOI: https://doi.org/10.1016/j.jaad.2019.10.039
Saeedi Borujeni MJ, Esfandiary E, Taheripak G, Codoñer-Franch P, Alonso-Iglesias E, Mirzaei H. Molecular aspects of diabetes mellitus: resistin, microRNA, and exosome. J Cell Biochem 2018; 119: 1257-1272.
https://doi.org/10.1002/jcb.26271 DOI: https://doi.org/10.1002/jcb.26271
McTernan CL, McTernan P, Harte A, Levick P, Barnett A, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-47.
https://doi.org/10.1016/S0140-6736(02)07281-1 DOI: https://doi.org/10.1016/S0140-6736(02)07281-1
Kizilarslanoğlu MC, Kara Ö, Yeşil Y, Kuyumcu ME, Öztürk ZA, Cankurtaran M, et al. Alzheimer's disease, inflammation, and novel inflammatory marker: resistin. Turk J Med Sci 2015; 45: 1040-1046.
https://doi.org/10.3906/sag-1403-55 DOI: https://doi.org/10.3906/sag-1403-55
Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, et al. Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimers Dement (Amst) 2015; 1: 339-348.
https://doi.org/10.1016/j.dadm.2015.06.008 DOI: https://doi.org/10.1016/j.dadm.2015.06.008
Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795.
https://doi.org/10.4049/jimmunol.174.9.5789 DOI: https://doi.org/10.4049/jimmunol.174.9.5789
Damsgaard TE, Olesen AB, Sørensen FB, Thestrup-Pedersen K, Schiøtz PO. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch Dermatol Res 1997; 289: 256-260.
https://doi.org/10.1007/s004030050189 DOI: https://doi.org/10.1007/s004030050189
Kjellman NI, Gustafsson I. Topical sodium cromoglycate in atopic dermatitis a disappointing but informative trial. Allergy 1986; 41: 423-428.
https://doi.org/10.1111/j.1398-9995.1986.tb00322.x DOI: https://doi.org/10.1111/j.1398-9995.1986.tb00322.x
Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001; 44: 89-93.
https://doi.org/10.1067/mjd.2001.111352 DOI: https://doi.org/10.1067/mjd.2001.111352
Hamdy N, Salam RF, Mohamed NAE-G. Mast cell, a new player in type 2 diabetes. Kasr Al Ainy Medical Journal 2018; 24: 59.
https://doi.org/10.4103/kamj.kamj_18_18 DOI: https://doi.org/10.4103/kamj.kamj_18_18
Skaper SD, Facci L, Romanello S, Leon A. Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J Neurochem 1996; 66: 1157-1166.
https://doi.org/10.1046/j.1471-4159.1996.66031157.x DOI: https://doi.org/10.1046/j.1471-4159.1996.66031157.x
Kempuraj D, Selvakumar GP, Thangavel R, Ahmed ME, Zaheer S, Raikwar SP, et al. Mast cell activation in brain injury, stress, and post-traumatic stress disorder and Alzheimer's disease pathogenesis. Front Neurosci 2017; 11: 703.
https://doi.org/10.3389/fnins.2017.00703 DOI: https://doi.org/10.3389/fnins.2017.00703
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Yu Ri Woo, Minah Cho, Kyung Do Han, Sang Hyun Cho, Ji Hyun Lee
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
